This site requires Javascript to be enabled on many pages
π½οΈ cefazolin sodium salt (antibiotic)
AI Engines For more Details:
Perplexity
Kagi Labs
You
(altazolin, avezol-aversi, biofazolin, cefa, cefacin, cefamezin, cefazol, cefazolin actavis, cefazolin balkanpharma-razgrad, cefazolin bcpp, cefazolin biocheme, cefazolin biochemie, cefazolin biopolus, cefazolin h.g., cefazolin habit, cefazolin hospira, cefazolin indo farma, cefazolin ipp pharma, cefazolin kievmedpreparat, cefazolin nycomed, cefazolin rup borisov, cefazolin sandoz, cefazolin teva, cefazolina, cefazolina magma, cefazolina max vision, cefazolina medisumi, cefazolina opko, cefazolina richet, cefazolina vitalis, cefazolin-bcpp, cefazolin-mip, cefizol, cefovet, cefovet dc, cefovet l, cefovet ts, cellozina, cezolin, cifoxim, kefzol, maksiporin, orizolin, pan-cefazolin, primaceph, reflin, sefazol, sezolin, suporin, tarfazolin, totacef, zepilen, zinol, zolidina, 2 world cefazolin, adco-cefazolin, adco-cefotaxime, areuzolin, aspen cefazolin, basocef-actavis, biozolin, cefacidal, cefalomicina, cefamezin alfa, cefarizon, cefazil, cefazo, cefazole, cefazolin - hisun pharm, cefazolin - taiyang pharm, cefazolin aft, cefazolin apotex, cefazolin ccpc, cefazolin chi sheng, cefazolin gentle, cefazolin hexal, cefazolin labatec, cefazolin meiji, cefazolin mip, cefazolin na otsuka, cefazolin na taiyo, cefazolin ogbdexa, cefazolin oriental, cefazolin panpharma, cefazolin sodium - guilin pharma, cefazolin sodium - likang, cefazolin sodium - new asiatic, cefazolin sodium - north china pharm, cefazolin sodium nichi-iko, cefazolin sodium-cspc pharm, cefazolin steripharma, cefazolin yung shin, cefazolina biosano, cefazolina farmalogica, cefazolina genfar, cefazolina genfarma, cefazolina germed, cefazolina k24, cefazolina l.ch., cefazolina normon, cefazolina northia, cefazolina reig jofre, cefazolina sala, cefazolina teva, cefazolin-aft, cefazoline cf, cefazoline hospira, cefazoline mylan, céfazoline mylan, cefazoline panpharma, céfazoline panpharma, cefazoline sandoz, cefazolin-fresenius, cefazolin-fresenius vials, cefazolin-saar, cefazovit, cefemezine, cefozin, ceftrat, cephazolin alphapharm, cezol, cizo, cloviz, cromezin, dbl cephazolin sodium, eqizolin, evalin, fazolin, fazonil, fonvicol, galecef, hazolin, iespor, ilozef, intralin, kefazol, kelin, kofatol, kurgan, leklin, lofalin, mylan cefazolin, nefazol, ranzol, rasenazolin, saifuning, seafar, stancef, stazolin, tasep, tecfazolina, tefazol, tokio, uzolin, venozol, veterin, vifazolin, vulmizolin, winzolin, xintailin, zefkol, zofadep, zolfas, zolival)
Impacted of cefazolin sodium salt (antibiotic) On Probiotics
Rank
Probiotic
Impact
species
Akkermansia muciniphila
Reduces
species
Bifidobacterium adolescentis
Reduces
species
Bifidobacterium longum
Reduces
species
Escherichia coli
Reduces
species
Lacticaseibacillus paracasei
Reduces
subspecies
Bifidobacterium longum subsp. infantis
Reduces
subspecies
Bifidobacterium longum subsp. longum
Reduces
Bacteria Impacted by cefazolin sodium salt (antibiotic)
We extend modifiers to include items that changes the parent and child taxa. I.e. for a species , that would be the genus that is belongs to and the strains in the species.
π§?
Taxonomy
Rank
Effect
Citations
Notation
Collinsella
genus
Decreases
👪 Source Study
proinflammatory
Lacrimispora
genus
Decreases
👪 Source Study
Clostridium
genus
Decreases
👪 Source Study
Pathogen
Streptococcus
genus
Decreases
👪 Source Study
Phocaeicola
genus
Decreases
👪 Source Study
Escherichia
genus
Decreases
👪 Source Study
Mediterraneibacter
genus
Decreases
👪 Source Study
Bifidobacterium
genus
Decreases
👪 Source Study
Fusobacterium
genus
Decreases
👪 Source Study
Periodontal disease, Lemierre syndrome, skin ulcers
Dorea
genus
Decreases
👪 Source Study
Veillonella
genus
Decreases
👪 Source Study
Odoribacter
genus
Decreases
👪 Source Study
Coprococcus
genus
Decreases
👪 Source Study
Thomasclavelia
genus
Decreases
👪 Source Study
Lachnospira
genus
Decreases
👪 Source Study
Blautia
genus
Decreases
👪 Source Study
Parabacteroides
genus
Decreases
👪 Source Study
BMI, fat percent,blood pressure
Ruminococcus
genus
Decreases
👪 Source Study
Segatella
genus
Decreases
👪 Source Study
Roseburia
genus
Decreases
👪 Source Study
Agathobacter
genus
Decreases
👪 Source Study
Bilophila
genus
Decreases
👪 Source Study
High Level Cause Brain Fog(Cognitive impairment)
Eggerthella
genus
Decreases
👪 Source Study
Lacticaseibacillus
genus
Decreases
👪 Source Study
Bacteroides
genus
Decreases
👪 Source Study
Akkermansia
genus
Decreases
👪 Source Study
Clostridioides
genus
Decreases
👪 Source Study
Enterocloster
genus
Decreases
👪 Source Study
Staphylococcus
genus
Decreases
👪 Source Study
Escherichia coli O80:H26
no rank
Decreases
👶 Source Study
Escherichia coli O145
serogroup
Decreases
👶 Source Study
Escherichia coli O157
serogroup
Decreases
👶 Source Study
Escherichia coli O26
serogroup
Decreases
👶 Source Study
Escherichia coli O43
serogroup
Decreases
👶 Source Study
Escherichia coli O1:H42
serotype
Decreases
👶 Source Study
Escherichia coli O104:H4
serotype
Decreases
👶 Source Study
Escherichia coli O121:H19
serotype
Decreases
👶 Source Study
Escherichia coli O127:H6
serotype
Decreases
👶 Source Study
Escherichia coli O139:H28
serotype
Decreases
👶 Source Study
Escherichia coli O157:H7
serotype
Decreases
👶 Source Study
bloody diarrhea
Escherichia coli O44:H18
serotype
Decreases
👶 Source Study
Escherichia coli O55:H7
serotype
Decreases
👶 Source Study
Escherichia coli O6:H16
serotype
Decreases
👶 Source Study
Escherichia coli O7:K1
serotype
Decreases
👶 Source Study
Collinsella aerofaciens
species
Decreases
📓 Source Study
Lacrimispora saccharolytica
species
Decreases
📓 Source Study
Clostridium perfringens
species
Decreases
📓 Source Study
Food poisoning, gas gangrene
Parabacteroides merdae
species
Decreases
📓 Source Study
Infectious bacteria
Streptococcus parasanguinis
species
Decreases
📓 Source Study
Streptococcus salivarius
species
Decreases
📓 Source Study
Infectious bacteria
Bacteroides uniformis
species
Decreases
📓 Source Study
Infectious bacteria
[Ruminococcus] torques
species
Decreases
📓 Source Study
Phocaeicola vulgatus
species
Decreases
📓 Source Study
Escherichia coli
species
Decreases
📓 Source Study
Diarrheal disease in children and travelers, Foodborne diarrhea outbreaks, hemorrhagic colitis, hemolytic-uremic syndrome
[Ruminococcus] gnavus
species
Decreases
📓 Source Study
Bifidobacterium adolescentis
species
Decreases
📓 Source Study
Bifidobacterium longum
species
Decreases
📓 Source Study
Fusobacterium nucleatum
species
Decreases
📓 Source Study
Infectious bacteria
Bacteroides caccae
species
Decreases
📓 Source Study
Dorea formicigenerans
species
Decreases
📓 Source Study
Veillonella parvula
species
Decreases
📓 Source Study
Odoribacter splanchnicus
species
Decreases
📓 Source Study
Coprococcus comes
species
Decreases
📓 Source Study
Thomasclavelia ramosa
species
Decreases
📓 Source Study
Lachnospira eligens
species
Decreases
📓 Source Study
Blautia obeum
species
Decreases
📓 Source Study
Bacteroides fragilis
species
Decreases
📓 Source Study
H02076 Bacteroides infection
Ruminococcus bromii
species
Decreases
📓 Source Study
Parabacteroides distasonis
species
Decreases
📓 Source Study
Segatella copri
species
Decreases
📓 Source Study
Over 70%ile Indicator of mycotoxin present
Roseburia hominis
species
Decreases
📓 Source Study
Roseburia intestinalis
species
Decreases
📓 Source Study
Bacteroides ovatus
species
Decreases
📓 Source Study
Agathobacter rectalis
species
Decreases
📓 Source Study
Bacteroides xylanisolvens
species
Decreases
📓 Source Study
Bilophila wadsworthia
species
Decreases
📓 Source Study
Eggerthella lenta
species
Decreases
📓 Source Study
Lacticaseibacillus paracasei
species
Decreases
📓 Source Study
Akkermansia muciniphila
species
Decreases
📓 Source Study
Bacteroides thetaiotaomicron
species
Decreases
📓 Source Study
Clostridioides difficile
species
Decreases
📓 Source Study
Colitis
Enterocloster bolteae
species
Decreases
📓 Source Study
Staphylococcus aureus
species
Decreases
📓 Source Study
Skin infections, sinusitis, food poisoning
Asaccharospora irregularis
species
Decreases
⚗️ Source Study
Lactonifactor longoviformis
species
Decreases
⚗️ Source Study
Staphylococcus aureus 04-02981
strain
Decreases
👶 Source Study
Staphylococcus aureus 07-03450
strain
Decreases
👶 Source Study
Staphylococcus aureus SK6575
strain
Decreases
👶 Source Study
Staphylococcus aureus subsp. aureus Mu50
strain
Decreases
👶 Source Study
H00330 Methicillin-resistant Staphylococcal aureus (MRSA) infection
Staphylococcus aureus subsp. aureus MW2
strain
Decreases
👶 Source Study
H00330 Methicillin-resistant Staphylococcal aureus (MRSA) infection
Staphylococcus aureus subsp. aureus N315
strain
Decreases
👶 Source Study
H00330 Methicillin-resistant Staphylococcal aureus (MRSA) infection
Bifidobacterium longum subsp. infantis
subspecies
Decreases
👶 Source Study
Bifidobacterium longum subsp. longum
subspecies
Decreases
👶 Source Study
Bifidobacterium longum subsp. suillum
subspecies
Decreases
👶 Source Study
Fusobacterium nucleatum subsp. nucleatum
subspecies
Decreases
👶 Source Study
Lacticaseibacillus paracasei subsp. paracasei
subspecies
Decreases
👶 Source Study
Staphylococcus aureus aureus
subspecies
Decreases
👶 Source Study
Impact of cefazolin sodium salt (antibiotic) on Conditions from US National Library of Medicine
A higher number indicates impact on more bacteria associated with the condition and confidence on the impact.
We have X bacteria high and Y low reported. We find that the modifier reduces some and increases other of these two groups.
We just tally: X|reduces + Y|Increase = Positive X|increases + Y|decrease = Negative.
Benefit Ratio:
Numbers above 0 have increasing positive effect.
Numbers below 0 have increasing negative effect.
Condition
Positive Impact
Negative Impact
Benefit Ratio Impact
Abdominal Aortic Aneurysm
0.5
0.5
Acne
0.5
-0.5
ADHD
7.5
1
6.5
Age-Related Macular Degeneration and Glaucoma
1
0.5
1
Allergic Rhinitis (Hay Fever)
3
2.5
0.2
Allergies
7.4
5
0.48
Allergy to milk products
2.5
1.5
0.67
Alopecia (Hair Loss)
2.5
2.5
Alzheimer's disease
6.5
10
-0.54
Amyotrophic lateral sclerosis (ALS) Motor Neuron
6
2.5
1.4
Ankylosing spondylitis
6.5
3
1.17
Anorexia Nervosa
0.5
3.5
-6
Antiphospholipid syndrome (APS)
3.7
0.5
6.4
Asthma
2.5
3
-0.2
Atherosclerosis
2
3.5
-0.75
Atrial fibrillation
5.5
3.5
0.57
Autism
16.5
15.5
0.06
Barrett esophagus cancer
1
0.5
1
benign prostatic hyperplasia
0.5
0.5
Bipolar Disorder
2.5
2.5
0
Brain Trauma
1
1.2
-0.2
Carcinoma
6
4
0.5
Celiac Disease
4.2
6.5
-0.55
Cerebral Palsy
2.5
2
0.25
Chronic Fatigue Syndrome
8.8
10
-0.14
Chronic Kidney Disease
4
3
0.33
Chronic Lyme
1
-1
Chronic Obstructive Pulmonary Disease (COPD)
3.5
1.5
1.33
Chronic Urticaria (Hives)
3
3
0
Coagulation / Micro clot triggering bacteria
3
2
0.5
Colorectal Cancer
8
1.5
4.33
Constipation
2.5
1
1.5
Coronary artery disease
2.5
1.5
0.67
COVID-19
19
23
-0.21
Crohn's Disease
13.5
9.5
0.42
cystic fibrosis
1.5
1.5
0
deep vein thrombosis
2
1.5
0.33
Depression
16.3
14
0.16
Dermatomyositis
0.5
0.5
0
Eczema
2
3.5
-0.75
Endometriosis
5
2
1.5
Eosinophilic Esophagitis
0.5
0.5
0
Epilepsy
5
4.5
0.11
Fibromyalgia
4.5
4.5
0
Functional constipation / chronic idiopathic constipation
10
6.5
0.54
gallstone disease (gsd)
3.5
1.5
1.33
Gastroesophageal reflux disease (Gerd) including Barrett's esophagus
3
1.5
1
Generalized anxiety disorder
3.5
3
0.17
giant cell arteritis
0.5
-0.5
Glioblastoma
0.5
-0.5
Gout
0.5
-0.5
Graves' disease
2
2
0
Halitosis
1.5
0.5
2
Hashimoto's thyroiditis
4
1.5
1.67
Hidradenitis Suppurativa
1.7
0.5
2.4
Histamine Issues,Mast Cell Issue, DAO Insufficiency
5.5
1.5
2.67
hypercholesterolemia (High Cholesterol)
1
1
0
hyperglycemia
0.7
3.5
-4
Hyperlipidemia (High Blood Fats)
1.5
0.5
2
hypersomnia
1
-1
hypertension (High Blood Pressure
4.2
8.2
-0.95
Hypothyroidism
2
-2
Hypoxia
1.5
1.5
IgA nephropathy (IgAN)
7
-7
Inflammatory Bowel Disease
8.2
14
-0.71
Insomnia
1.5
1.5
0
Intelligence
2
1
1
Intracranial aneurysms
2
0.5
3
Irritable Bowel Syndrome
7.5
7
0.07
Liver Cirrhosis
8.7
5.7
0.53
Long COVID
13.8
14
-0.01
Low bone mineral density
1.5
-1.5
Lung Cancer
1.5
2.5
-0.67
ME/CFS with IBS
1.9
4
-1.11
ME/CFS without IBS
3.5
3.5
0
Menopause
3
3
Metabolic Syndrome
13.7
14.6
-0.07
Mood Disorders
21.3
14.5
0.47
multiple chemical sensitivity [MCS]
2.5
0.5
4
Multiple Sclerosis
10
9
0.11
Multiple system atrophy (MSA)
3.5
1.5
1.33
Neuropathy (all types)
1.5
0.5
2
neuropsychiatric disorders (PANDAS, PANS)
1.5
1.5
Nonalcoholic Fatty Liver Disease (nafld) Nonalcoholic
4
8.5
-1.13
NonCeliac Gluten Sensitivity
0.5
-0.5
Obesity
14.2
8.7
0.63
obsessive-compulsive disorder
11.1
7.5
0.48
Osteoarthritis
4
0.5
7
Osteoporosis
3
2
0.5
pancreatic cancer
1
1
Parkinson's Disease
6
7
-0.17
Polycystic ovary syndrome
4
3.5
0.14
Postural orthostatic tachycardia syndrome
0.5
1
-1
Premenstrual dysphoric disorder
1.5
0.5
2
primary biliary cholangitis
0.5
1.5
-2
Psoriasis
8
5
0.6
rheumatoid arthritis (RA),Spondyloarthritis (SpA)
11.7
6
0.95
Rosacea
2
1
1
Schizophrenia
11.5
3
2.83
scoliosis
0.5
2
-3
Sjögren syndrome
5
5
0
Sleep Apnea
2.5
2.5
0
Small Intestinal Bacterial Overgrowth (SIBO)
2.2
1
1.2
Stress / posttraumatic stress disorder
5.2
4.5
0.16
Systemic Lupus Erythematosus
7.5
3
1.5
Tic Disorder
2
2.5
-0.25
Tourette syndrome
0.5
0.5
0
Type 1 Diabetes
6.5
4.2
0.55
Type 2 Diabetes
14.2
12.5
0.14
Ulcerative colitis
5.2
9.5
-0.83
Unhealthy Ageing
10.2
3.5
1.91
All suggestions are computed solely on their predicted microbiome impact. Safety, side-effects etc must be evaluated by your medical professionals before starting. Some items suggests have significant risk of adverse consequences for some people.
Special thanks to David F Morrison and Geert Van Houcke for doing Quality Assurance.
Special thanks to Oliver Luk, B.Sc. (Biology) from
BiomeSight for spot checking the coding of data from the US National Library of Medicine
Copyright 2016-2024 Lassesen Consulting, LLC [2007], DBA, Microbiome Prescription. All rights served.
Permission to data scrap or reverse engineer is explicitly denied to all users. U.S. Code Title 18 PART I CHAPTER 47 Β§β―1030, CETS No.185, CFAA
Use of data on this site is prohibited except under written license. There is no charge for individual personal use. Use for any commercial applications or research requires a written license.
Caveat emptor: Analysis and suggestions are based on modelling (and thus infererence ) based on studies. The data sources are usually given for those that wish to consider alternative inferences. theories and models.
Inventions/Methodologies on this site are Patent Pending.
Microbiome Prescription do not make any representations that data or analyses available on this site is suitable for human diagnostic purposes, for informing treatment decisions, or for any other purposes and accept no responsibility or liability whatsoever for such use.
This site is not Health Insurance Portability and Accountability Act of 1996 (HIPAA) compliant.